4.5 Article

Hospitals Respond To Medicare Payment Shortfalls By Both Shifting Costs And Cutting Them, Based On Market Concentration

Journal

HEALTH AFFAIRS
Volume 30, Issue 7, Pages 1265-1271

Publisher

PROJECT HOPE
DOI: 10.1377/hlthaff.2011.0220

Keywords

-

Funding

  1. California HealthCare Foundation

Ask authors/readers for more resources

The coverage expansions planned under the Affordable Care Act are to be financed in part by slowing Medicare payment updates to hospitals, thereby reigniting the debate over whether low prices paid by public payers cause hospitals to increase prices to private insurers-a practice known as cost shifting. Recently, the Medicare Payment Advisory Commission (MedPAC) proposed an alternative explanation of hospital pricing and profitability that could be used to support policies that pressure hospitals to reduce overall costs rather than to only raise prices. This study evaluated the cost-shift and MedPAC perspectives using 2008 data on hospital margins for 30,514 Medicare and privately insured patients undergoing any of seven major procedures in markets where robust hospital competition exists and in markets where hospital care is concentrated in the hands of a few providers. The study presents empirical evidence that, faced with shortfalls between Medicare payments and projected costs, hospitals in concentrated markets focus on raising prices to private insurers, while hospitals in competitive markets focus on cutting costs. Policy makers need to examine whether efforts to promote clinical coordination through provider integration may interfere with efforts to restrain overall health care cost growth by restraining Medicare payment rates.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Health Care Sciences & Services

Reference Pricing Changes The 'Choice Architecture' Of Health Care For Consumers

James C. Robinson, Timothy T. Brown, Christopher Whaley

HEALTH AFFAIRS (2017)

Article Health Care Sciences & Services

Value-Based Physician Payment in Oncology: Public and Private Insurer Initiatives

James C. Robinson

MILBANK QUARTERLY (2017)

Article Medicine, General & Internal

Association of Reference Pricing with Drug Selection and Spending

James C. Robinson, Christopher M. Whaley, Timothy T. Brown

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Editorial Material Medicine, General & Internal

Medicare Advantage Reimbursement to Physicians

James C. Robinson

JAMA INTERNAL MEDICINE (2017)

Editorial Material Medicine, General & Internal

Value-Based Pricing and Patient Access for Specialty Drugs

James C. Robinson, Scott Howell, Steven D. Pearson

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

Editorial Material Medicine, General & Internal

Lower Prices and Greater Patient Access - Lessons from Germany's Drug-Purchasing Structure

James C. Robinson

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Editorial Material Medicine, General & Internal

Sophisticated Purchasing of Pharmaceuticals Learning From Other Countries

James C. Robinson

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Editorial Material Medicine, General & Internal

Funding of Pharmaceutical Innovation During and After the COVID-19 Pandemic

James C. Robinson

Summary: This viewpoint discusses the shift towards government funding of drug development during the COVID-19 pandemic, arguing that sustained public investment is necessary for affordable drug prices and U.S. global leadership.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Article Health Care Sciences & Services

Quantifying The Economic Burden Of Drug Utilization Management On Payers, Manufacturers, Physicians, And Patients

Scott Howell, Perry T. Yin, James C. Robinson

Summary: The launch of high-price but innovative drugs has led to increased efforts to manage utilization and spending from payers and support patient access and sales from pharmaceutical manufacturers. Existing literature estimates that approximately $93.3 billion is spent annually by payers, manufacturers, physicians, and patients on managing utilization.

HEALTH AFFAIRS (2021)

Article Health Care Sciences & Services

Competition From Biosimilars Drives Price Reductions For Biologics In The French Single-Payer Health System

James C. Robinson, Quentin Jarrion

Summary: France has a single-payer health insurance system that relies on decentralized market negotiations between hospitals and manufacturers to establish prices for biologics. Biosimilars are used to stimulate competition and drive price reductions, with biosimilar launches associated with reductions in prices for reference biologics and other related biologics.

HEALTH AFFAIRS (2021)

Article Health Care Sciences & Services

Price Differences To Insurers For Infused Cancer Drugs In Hospital Outpatient Departments And Physician Offices

James C. Robinson, Christopher M. Whaley, Timothy T. Brown

Summary: Research has shown that Blue Cross Blue Shield health plans paid double for cancer infusion drugs in hospital outpatient departments compared to physician offices in 2019. Shifting infusion care to nonhospital settings could result in significant savings for insurers, but would also increase cost-sharing burdens for patients.

HEALTH AFFAIRS (2021)

Editorial Material Medicine, General & Internal

Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform

James C. Robinson

Summary: The price of Aducanumab responds to key features of the physician-administered drug market environment, providing valuable information for the drug pricing policy debate.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Medicine, General & Internal

Physician and Patient Adjustment to Reference Pricing for Drugs

James C. Robinson, Christopher Whaley, Timothy T. Brown, Sanket S. Dhruva

JAMA NETWORK OPEN (2020)

Article Health Care Sciences & Services

Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations

Fabian Berkemeier, Christopher Whaley, James C. Robinson

JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2019)

No Data Available